Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780825 | 0.87 | AURKA (0.39) | CA1CA2 | |
| SCHEMBL2780555 | 0.81 | ADRA2A (0.44) | HDAC6 | |
| SCHEMBL3358172 | 0.80 | ACHE (0.35) | CA1CA2 | |
| SCHEMBL1924125 | 0.77 | HDAC6 (0.40) | HDAC6TRPV1IDO1 | |
| SCHEMBL2799990 | 0.76 | JAK2 (0.31) | — | |
| SCHEMBL3356170 | 0.76 | JAK2 (0.31) | — | |
| SCHEMBL13505029 | 0.76 | TRPM8 (0.37) | — | |
| SCHEMBL3360272 | 0.72 | PRKCI (0.36) | — | |
| SCHEMBL3428700 | 0.70 | AURKA (0.40) | HDAC6TRPV1CA12CA1CA2 | |
| SCHEMBL3231755 | 0.69 | AURKA (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | claimed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | claimed |
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | HDAC6 735/4885TRPV1 514/4885IDO1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.